Polatuzumab Vedotin Addition Makes Stark Difference for DLBCL Patients, Studies Show
News
Adding the investigational treatment polatuzumab vedotin to a therapy of Bendeka (bendamustine) and Rituxan (rituximab) made patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) respond better to the ... Read more